Successful treatment of atelectasis with Dornase alpha in a patient with congenital muscular dystrophy

Rev Port Pneumol. 2014 Jan-Feb;20(1):42-5. doi: 10.1016/j.rppneu.2012.12.002. Epub 2013 Oct 2.

Abstract

A 28-year-old neuromuscular patient chronically treated with nocturnal noninvasive ventilation developed pulmonary lobar atelectasis and daytime hypoxemia. Twenty four-hour 5L/min oxygen was begun, while mechanical cough assist aids were applied for seven days. In the following three days, treatment with nebulized Dornase alpha (rhDNase) b.i.d. was tested, without any significant improvement. On 11 and 13th days rhDNase was instilled by flexible bronchoscopy. A rapid resolution of the atelectasis was observed with relief of hypoxemia, without significant side effects. On day 16 the patient was discharged without oxygen requirements. In non-intubated neuromuscular patients with atelectasis who do not respond successfully to non-invasive treatments intrabronchial instillation of rhDNase may safely help to improve airway clearance.

Keywords: Atelectasia; Atelectasis; Doenças neuromusculares; Dornase alfa; Dornase alpha; Neuromuscular diseases.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Deoxyribonuclease I / therapeutic use*
  • Female
  • Humans
  • Muscular Dystrophies / complications*
  • Muscular Dystrophies / congenital*
  • Pulmonary Atelectasis / complications*
  • Pulmonary Atelectasis / drug therapy*
  • Recombinant Proteins / therapeutic use
  • Remission Induction

Substances

  • Recombinant Proteins
  • Deoxyribonuclease I
  • dornase alfa